Nanobiotix (NASDAQ:NBTX) Announces Earnings Results

Nanobiotix (NASDAQ:NBTX) announced its quarterly earnings data on Thursday. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.08, FiscalAI reports. The business had revenue of $3.17 million for the quarter, compared to analyst estimates of $1.73 million.

Nanobiotix Stock Down 5.1%

Nanobiotix stock opened at $33.46 on Friday. The company has a fifty day simple moving average of $38.82 and a 200-day simple moving average of $37.39. Nanobiotix has a 52-week low of $14.46 and a 52-week high of $57.14.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. Leerink Partners increased their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, June 4th. Finally, Guggenheim assumed coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nanobiotix currently has an average rating of “Moderate Buy” and a consensus target price of $46.67.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.